Long‐term cognitive and biomarker trajectories of cognitively unimpaired individuals with different levels of plasma ptau‐217

Abstract

Background: Plasma ptau‐217 has demonstrated excellent performance in detecting AD pathology. However, its value for predicting long‐term cognitive decline among cognitively unimpaired (CU) individuals remains unclear.